Coherus BioSciences, Inc. (CHRS)
| Market Cap | 1.32B |
| Revenue (ttm) | 394.65M |
| Net Income (ttm) | -165.21M |
| Shares Out | 75.56M |
| EPS (ttm) | -2.29 |
| PE Ratio | n/a |
| Forward PE | 32.89 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 526,431 |
| Open | 17.30 |
| Previous Close | 17.26 |
| Day's Range | 17.03 - 17.44 |
| 52-Week Range | 12.21 - 22.22 |
| Beta | 1.02 |
| Analysts | Buy |
| Price Target | 25.71 (+50.7%) |
| Est. Earnings Date | Nov 4, 2021 |
About CHRS
Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its product candidate pipeline includes biosimilars of Humira, Avastin, and Lucentis. The company also develops Toripalimab, a novel anti-PD-1 antibody for second-line treatment of melanoma in China; Bevacizumab biosimilar; CHS-1420, an anti-TNF product candidate, as an adalimuma...
Financial Performance
In 2020, CHRS's revenue was $475.82 million, an increase of 33.63% compared to the previous year's $356.07 million. Earnings were $132.24 million, an increase of 47.21%.
Financial StatementsAnalyst Forecast
According to 10 analysts, the average rating for CHRS stock is "Buy." The 12-month stock price forecast is 25.71, which is an increase of 50.70% from the latest price.
News
Coherus Management to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
REDWOOD CITY, Calif., Sept. 10, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that senior management will present at the 23rd Annual H.C. Wainwright Globa...
Coherus BioSciences Announces New Employment Inducement Grants
REDWOOD CITY, Calif., Aug. 27, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that effective Aug. 26, 2021, the compensation committee of ...
New Strong Sell Stocks for August 25th
BEEM, CHRS, KMDA, STIM and PHUN have been added to the Zacks Rank #5 (Strong Sell) List on August 25, 2021
Coherus (CHRS), Junshi Announce Positive NSCLC Study Results
Coherus BioSciences (CHRS) and partner Junshi announce positive data from a late-stage study on toripalimab for the first-line treatment of NSCLC.
Junshi and Coherus Biosciences Announce Positive Interim Results of CHOICE-01, a Phase 3 Clinical Trial Evaluating To...
– Toripalimab plus chemotherapy met primary endpoint with significant improvement in PFS compared to chemotherapy alone –
New Strong Sell Stocks for August 17th
ACCD, CHRS, ELVT, FLGT, and GSHD have been added to the Zacks Rank #5 (Strong Sell) List on August 17, 2021.
Coherus BioSciences (CHRS) Reports Q2 Loss, Tops Revenue Estimates
Coherus BioSciences (CHRS) delivered earnings and revenue surprises of -60.00% and 6.05%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Coherus BioSciences (CHRS) to Report a Decline in Earnings: What to Look Out for
Coherus BioSciences (CHRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Coherus BioSciences to Report Second Quarter 2021 Financial Results on August 5th
REDWOOD CITY, Calif., July 26, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that its second quarter 2021 financial results will be released after market ...
Coherus BioSciences Names Physician-Scientist Ildiko Csiki, M.D., Ph.D., Chair of its Scientific Advisory Board
- Csiki has over two decades of experience in research and drug development of cancer immunotherapies - - Csiki has over two decades of experience in research and drug development of cancer immunotherap...
Coherus BioSciences Announces New Employment Inducement Grants
REDWOOD CITY, Calif., July 12, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that effective July 6, 2021, the compensation committee of t...
Coherus, Junshi Toripalimab-Chemo Combo Beat Chemo Alone in Late-Stage Nose & Throat Cancer Trial
Shanghai Junshi Biosciences Co Ltd and Coherus BioSciences Inc (NASDAQ: CHRS) have announced positive results from the pivotal Phase 3 JUPITER-02 trial evaluating toripalimab plus chemotherapy for the f...
Coherus BioSciences to Present at the Bank of America Health Care Conference
REDWOOD CITY, Calif., May 07, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that senior management will present at the upcoming Bank of America Health Car...
Coherus BioSciences (CHRS) Reports Q1 Loss, Misses Revenue Estimates
Coherus BioSciences (CHRS) delivered earnings and revenue surprises of -2733.33% and -15.16%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Coherus BioSciences: Q1 Earnings Insights
Shares of Coherus BioSciences (NASDAQ:CHRS) were flat in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share decreased 97.92% year over year to $0.01, which ...
Coherus BioSciences to Report First Quarter 2021 Financial Results on May 6th
REDWOOD CITY, Calif., April 30, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or “the Company”, Nasdaq: CHRS), today announced that its first quarter 2021 financial results will be relea...
Analysts Estimate Coherus BioSciences (CHRS) to Report a Decline in Earnings: What to Look Out for
Coherus BioSciences (CHRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Coherus Announces Toripalimab Achieved Primary Endpoints of Progression Free Survival and Overall Survival in Interim...
REDWOOD CITY, Calif., April 23, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: CHRS) has received notice from immuno-oncology partner Junshi Biosciences that the Independent Data Monitoring...
Blade Therapeutics Announces Appointment of Jean-Frédéric Viret as Chief Financial Officer
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- #Blade--Blade Therapeutics announces the appointment of Jean-Frédéric Viret, Ph.D., as Chief Financial Officer (CFO) effective immediately.
3 Undervalued Biotechs Worth Adding to Your Watch List
Their recent struggles may soon give way to rising market interest and more lucrative returns.
Coherus Management to Present at Upcoming Investor Conferences
REDWOOD CITY, Calif., Feb. 25, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), announced today that senior management will present at the following investor conferences in ...
Coherus BioSciences (CHRS) Misses Q4 Earnings and Revenue Estimates
Coherus BioSciences (CHRS) delivered earnings and revenue surprises of -52.00% and -3.90%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Coherus BioSciences Reports Fourth Quarter and Full Year 2020 Financial Results
- Product revenues of $476 million for full year 2020, $110 million for the fourth quarter of 2020 - - Expanding late-stage opportunities with Junshi Biosciences immuno-oncology collaboration with firs...
Earnings Preview: Coherus BioSciences (CHRS) Q4 Earnings Expected to Decline
Coherus BioSciences (CHRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CHRS or ILMN: Which Is the Better Value Stock Right Now?
CHRS vs. ILMN: Which Stock Is the Better Value Option?